Britain and America have agreed to a major commercial pact that will maintain no tariffs on UK drug products being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This pledge ensures that tariffs on these key exports will stay at nothing for a duration of the next three years.
This development comes after previous statements to dramatically increase tariffs on patented drug products, with increases discussed as high as 100%.
"This agreement between the Britain reinforces the international landscape for cutting-edge drugs and introduces long-overdue balance to U.S.–U.K. pharmaceutical trade," an announcement noted.
Economic Significance
Medicines represent one of the the United Kingdom's largest goods shipped to the United States, which is easily the primary market for large companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period prior to last September, the UK sold drugs worth billions to the US. This value accounted for a significant portion of all goods exports in that timeframe.
"This guarantee secures work, boosts investment and facilitates the UK to establish itself as a international leader for medical research," a minister commented.
Key NHS Changes
The pact involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a aim to increase total NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at 15%. Previously, repayments exceeded 20%.
Industry Background
The deal takes place against a long-running tension between the pharmaceutical industry and the ministers over spending levels and approval rates.
This friction were intensified by claims that American consumers were paying significantly more for the identical medicines than people in the UK and Europe.
Recently, several significant drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the last ten years.
